We now expect to finish fiscal 2024 with approximately $35,000,000 to $38,000,000 in cash and investments, representing a year over year decrease of $10,000,000 to $7,000,000 Our updated expectation represents an improvement of $6,000,000 to $7,000,000 compared to the expectations shared on our Q1 earnings call, driven by improved operating performance. As we have discussed in detail on recent earnings calls during fiscal 2023, cash and investments increased $26,000,000 reflecting an influx of cash from the $27,000,000 milestone payment on receiving PMA for the SurVeil drug coated balloon, as well as $19,300,000 in net debt proceeds from our term loan and revolving credit facility. Sitting aside these items, cash and investments expectations for fiscal 2024 year end cash and investments reflects an improvement in cash use of $10,000,000 to $13,000,000 compared to the $20,000,000 in fiscal 2023 I just mentioned. Our expectations for fiscal 2024 year end cash and investments continue to reflect the following assumptions. Capital expenditures of up to $5,000,000 compared to $2,900,000 in fiscal 2023, which includes certain investments postponed last year as part of our spending reduction plan and payments totaling $2,700,000 to satisfy obligations related previous acquisitions, of which $930,000 was paid during the Q2.